Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IPHA logo IPHA
Upturn stock ratingUpturn stock rating
IPHA logo

Innate Pharma (IPHA)

Upturn stock ratingUpturn stock rating
$1.85
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: IPHA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.86

1 Year Target Price $7.86

Analysts Price Target For last 52 week
$7.86Target price
Low$1.29
Current$1.85
high$3.51

Analysis of Past Performance

Type Stock
Historic Profit -67.58%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 167.27M USD
Price to earnings Ratio -
1Y Target Price 7.86
Price to earnings Ratio -
1Y Target Price 7.86
Volume (30-day avg) 3
Beta 0.98
52 Weeks Range 1.29 - 3.51
Updated Date 07/1/2025
52 Weeks Range 1.29 - 3.51
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.7

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -245.87%
Operating Margin (TTM) -324.87%

Management Effectiveness

Return on Assets (TTM) -22.52%
Return on Equity (TTM) -162.91%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 110148262
Price to Sales(TTM) 8.31
Enterprise Value 110148262
Price to Sales(TTM) 8.31
Enterprise Value to Revenue 7.45
Enterprise Value to EBITDA -6.94
Shares Outstanding 92157800
Shares Floating 59214654
Shares Outstanding 92157800
Shares Floating 59214654
Percent Insiders -
Percent Institutions 0.24

Analyst Ratings

Rating 2
Target Price 7.86
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Innate Pharma

stock logo

Company Overview

overview logo History and Background

Innate Pharma S.A. is a French biopharmaceutical company dedicated to improving treatment through innovative therapeutic antibodies that exploit the innate immune system. Founded in 1999, it has grown through research partnerships and clinical development.

business area logo Core Business Areas

  • Research and Development: Focused on discovering and developing first-in-class immunotherapies for cancer and inflammatory diseases. Targets include NK cell receptors and other immune checkpoints.
  • Licensing and Partnerships: Generating revenue through licensing agreements and strategic collaborations with pharmaceutical companies to develop and commercialize Innate Pharma's assets.

leadership logo Leadership and Structure

The company is led by a management team with expertise in immunotherapy and drug development. Its organizational structure includes research, clinical development, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Monalizumab: A checkpoint inhibitor targeting NKG2A, co-developed with AstraZeneca. Aims to restore anti-cancer immunity by blocking the NKG2A receptor on tumor-infiltrating lymphocytes and NK cells. Clinical trials are ongoing in various cancers. Market share is currently pre-commercialization. Competitors include PD-1/PD-L1 inhibitors from Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).
  • Lacutamab: Anti-KIR3DL2 antibody in clinical trials for cutaneous T-cell lymphoma. Currently pre-commercialization. Competitors include other therapies for CTCL, such as Mogamulizumab (Poteligeo) from Kyowa Kirin.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system's role in cancer and other diseases. It is dominated by checkpoint inhibitors, cell therapies, and other novel approaches.

Positioning

Innate Pharma focuses on innate immunity, a less-explored area compared to adaptive immunity. This potentially gives them a competitive advantage through differentiated targets and mechanisms of action.

Total Addressable Market (TAM)

The global immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. Innate Pharma is positioned to capture a portion of this market through its innovative pipeline, focusing on areas of unmet need such as NK cell-based therapies.

Upturn SWOT Analysis

Strengths

  • Innovative pipeline targeting innate immunity
  • Strategic partnerships with major pharmaceutical companies (AstraZeneca)
  • Strong expertise in antibody engineering and immunology
  • Focus on novel targets (NKG2A, KIR3DL2)

Weaknesses

  • Reliance on partnerships for commercialization
  • High R&D expenses
  • Clinical trial risks and uncertainties
  • Relatively small company size compared to major players

Opportunities

  • Expansion of existing partnerships
  • Potential for breakthrough therapies in underserved markets
  • Acquisition or merger by a larger pharmaceutical company
  • Positive clinical trial results

Threats

  • Competition from established immunotherapy companies
  • Failure of clinical trials
  • Regulatory hurdles and delays
  • Pricing pressures on new therapies

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • RHHBY
  • KYKOF

Competitive Landscape

Innate Pharma differentiates itself through its focus on innate immunity, but it faces competition from larger companies with more resources and established products. Its partnerships are critical for its competitive positioning.

Growth Trajectory and Initiatives

Historical Growth: Innate Pharma's growth has been driven by its research and development pipeline, partnerships, and milestones achieved in clinical trials.

Future Projections: Future growth depends on the success of ongoing clinical trials and the commercial potential of its pipeline assets. Analyst estimates vary.

Recent Initiatives: Recent initiatives include advancing clinical trials for Monalizumab and Lacutamab, and expanding research collaborations to discover new targets.

Summary

Innate Pharma is a promising biopharmaceutical company focusing on novel immunotherapy approaches. Its strength lies in its innovative pipeline and strategic partnerships. However, it faces risks associated with clinical trial outcomes, competition, and reliance on partners. Positive clinical data and successful commercialization will be crucial for its future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Innate Pharma

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-10-17
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 181
Full time employees 181

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.